CS
GYRE icon

Credit Suisse’s Gyre Therapeutics GYRE Stock Holding History

Credit Suisse’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,142
Closed -$138K – 4062
2020
Q2 		$138K Sell
3,142
-13,718
-81% -$644K ﹤0.01% 3802
2020
Q1 		$553K Buy
16,860
+3,380
+25% +$155K ﹤0.01% 3050
2019
Q4 		$688K Buy
+13,480
New +$565K ﹤0.01% 3375
2014
Q3 		– Sell
-55
Closed -$195K – 4518
2014
Q2 		$195K Buy
55
+24
+77% +$78.3K ﹤0.01% 4377
2014
Q1 		$116K Sell
31
-32
-51% -$118K ﹤0.01% 4492
2013
Q4 		$205K Buy
63
+37
+142% +$146K ﹤0.01% 4315
2013
Q3 		$107K Sell
26
-43
-62% -$173K ﹤0.01% 4096
2013
Q2 		$232K Buy
+69
New +$263K ﹤0.01% 3794

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Credit Suisse's GYRE Position: Q3 2020 in Review

Credit Suisse sold out of Gyre Therapeutics (GYRE) in Q3 2020, closing a stake of 3,142 shares — an estimated $138K sold.

Credit Suisse first reported a position in GYRE in Q2 2013 and held it in 8 quarters. The position peaked at $688K in Q4 2019. 78 funds tracked by Wall St. Rank hold GYRE as of Q3 2020.

  • Credit Suisse reported no remaining Gyre Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Credit Suisse sold 3,142 Gyre Therapeutics shares in Q3 2020, an estimated $138K.
  • Credit Suisse first reported a position in Gyre Therapeutics in Q2 2013 and held it in 8 quarters.
  • Credit Suisse's Gyre Therapeutics position peaked at $688K in Q4 2019.
  • 78 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2020.

Based on Credit Suisse's 13F filing for Q3 2020, filed 13 Nov 2020.